Pfizer breathes easy with Exubera data
Type 1 and type 2 diabetes patients do not experience greater reductions in lung function with long-term use of Pfizer's inhaled insulin Exubera, the firm says. Data from an eight-year extension study of 217 adults from the three Phase III Exubera trials show the average yearly reductions in lung function were similar between treatment and control groups, Pfizer says. Lung function tests are advised in product labeling for initiation of therapy and regular monitoring for the inhaled product (1"The Pink Sheet" Feb. 13, 2006, p. 23). The study, presented at the European Association for the Study of Diabetes Sept. 18, also shows that blood sugar levels were maintained with long-term Exubera use. Pfizer also presents data from an eight-day study comparing Exubera to Sanofi-Aventis' long-acting insulin Lantus in uncontrolled type 2 diabetics. The 40-patient study shows "no differences in the blood sugar variability endpoints between Exubera and Lantus," Pfizer says, adding that additional large-scale studies comparing the insulins are ongoing...
You may also be interested in...
Pfizer's mid-year launch timeline for its inhaled insulin therapy Exubera is influenced by the need to educate physicians, complex supply chain issues and reimbursement discussions, Pfizer co-development partner Nektar suggested
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.